Yesterday, the EVP,Finance & Strategy and CFO of Ligand Pharma (LGND), Matthew Korenberg, bought shares of LGND for $43.09K.
In addition to Matthew Korenberg, 4 other LGND executives reported Buy trades in the last month. Following this transaction Matthew Korenberg’s holding in the company was increased by 3% to a total of $1.5 million.
See today’s analyst top recommended stocks >>
The company has a one-year high of $278.62 and a one-year low of $85.87. Currently, Ligand Pharma has an average volume of 500.93K. LGND’s market cap is $1.66B and the company has a P/E ratio of 2.78.
The insider sentiment on Ligand Pharma has been positive according to 55 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
